Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Sucampo Pharmaceuticals, Inc. | exh_992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2014
|
Sucampo Pharmaceuticals, Inc.
|
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-33609
|
30-0520478
|
|
(State or Other Juris-
diction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
4520 East-West Highway, 3rd Floor
Bethesda, Maryland
|
20814
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (301) 961-3400
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
This current report on Form 8K/A (this “Amendment”) amends the current report on Form 8K, filed February 12, 2014 (the “Original Filing”), in which Sucampo Pharmaceuticals, Inc. (the “Company”) reported a corporate update presentation at one-on-one meetings with analysts and investors in New York City, NY at the Leerink Swann Global Healthcare Conference 2014. All meetings included the slides filed on Form 8K dated January 13, 2014 including modifications to five slides. The Company is filing this Amendment to include the revised Leadership Transition slide to correct the years of transition to indicate March 2014. Except for the foregoing, this Amendment does not amend, modify or update the disclosures contained in the Original Filing. The Company updated the slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit relating to Item 5.02 and 7.01 shall be deemed to be furnished, and not filed:
99.2 The modifications of the Leadership Transition slide dated February 13, 2014.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SUCAMPO PHARMACEUTICALS, INC.
|
||
|
Date: February 13, 2014
|
By: |
/s/ Thomas J. Knapp
|
|
Name: Thomas J. Knapp
Title: EVP, Chief Legal Officer and Corporate Secretary
|